Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Want to cut your energy bills? Here’s how five experts are doing it 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
TEL AVIV, Israel, March 07, 2017 -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced it will provide a corporate overview at the 29th Annual ROTH Conference, being held March 12-15, 2017 at the Ritz Carlton in Dana Point, California.
| VBL Therapeutics Presentation Details @ 29th Annual ROTH Conference | ||
| Date: | Tuesday, March 14th | |
| Time: | 7:30am Pacific Time/10:30am Eastern Time | |
| Presentation Room: | Blue - Salon 2 | |
About VBL
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is positioned to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >200 cancer patients and we have observed its efficacy signals in an “all comers” Phase 1 trial as well as in three tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a Phase 3 pivotal trial for recurrent Glioblastoma, conducted under an FDA Special Protocol Assessment (SPA).
INVESTOR CONTACT: Michael Rice LifeSci Advisors, LLC (646) 597-6979
